Technology Bundle ID
TAB-3507

Salt and Crystal Forms of 2R,6R-Hydroxynorketamine for the Treatment of Depression

Applications
Linked ID
E-128-2019-0
Lead Inventors
Craig Thomas (NCATS)
Co-Inventors
Patrick Morris (NCATS)
ICs
This technology includes two new salt forms for (2R,6R)-hydroxynorketamine (2R,6R-HNK), which is the lead molecule being developed for treatment-resistant depression. Currently, 2R,6R-HNK is being developed as the HCl salt. The HCl salt is slightly hygroscopic at high RH. This is a potential liability, especially in an oral pill form. Recently the malonate and salicylate salt have been discovered and found to have excellent crystalline behavior while also not having the hygroscopic liability the HCl salt holds. This represents a clear advantage.
Commercial Applications
This can form the basis of a solid oral formulation for 2R,6R-HNK, as the malonate or salicylate salt.
Competitive Advantages
Two new salt forms have been discovered which have good crystallinity and do not have the hygrocopicity that the HCl salt possesses.

Request More Info

Licensing Contact: